《与非进展性感染相关的HIV-1多态性》

  • 来源专题:艾滋病防治
  • 编译者: 李越
  • 发布时间:2005-04-16
  • Factors accounting for long-term nonprogression may include infection with an attenuated strain of human immunodeficiency virus type 1 (HIV-1), genetic polymorphisms in the host, and virus-specific immune responses. In this study, we examined eight individuals with nonprogressing or slowly progressing HIV-1 infection, none of whom were homozygous for host-specific polymorphisms (CCR5-Δ32, CCR2-64I, and SDF-1-3′A) which have been associated with slower disease progression. HIV-1 was recovered from seven of the eight, and recovered virus was used for sequencing the full-length HIV-1 genome; full-length HIV-1 genome sequences from the eighth were determined following amplification of viral sequences directly from peripheral blood mononuclear cells (PBMC). Longitudinal studies of one individual with HIV-1 that consistently exhibited a slow/low growth phenotype revealed a single amino acid deletion in a conserved region of the gp41 transmembrane protein that was not seen in any of 131 envelope sequences in the Los Alamos HIV-1 sequence database. Genetic analysis also revealed that five of the eight individuals harbored HIV-1 with unusual 1- or 2-amino-acid deletions in the Gag sequence compared to subgroup B Gag consensus sequences. These deletions in Gag have either never been observed previously or are extremely rare in the database. Three individuals had deletions in Nef, and one had a 4-amino-acid insertion in Vpu. The unusual polymorphisms in Gag, Env, and Nef described here were also found in stored PBMC samples taken 3 to 11 years prior to, or in one case 4 years subsequent to, the time of sampling for the original sequencing. In all, seven of the eight individuals exhibited one or more unusual polymorphisms; a total of 13 unusual polymorphisms were documented in these seven individuals. These polymorphisms may have been present from the time of initial infection or may have appeared in response to immune surveillance or other selective pressures. Our results indicate that unusual, difficult-to-revert polymorphisms in HIV-1 can be found associated with slow progression or nonprogression in a majority of such cases.
  • 原文来源:http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=111953
相关报告
  • 《德罗特韦/利匹韦林:HIV-1感染综述》

    • 来源专题:重大新药创制—研发动态
    • 编译者:杜慧
    • 发布时间:2018-11-11
    • 德罗特韦/利匹韦林(Juluca®)是第一种被批准用于治疗成人HIV-1感染的双药单片剂方案(STR)。该固定剂量的STR方案含有整合酶链转移抑制剂德罗特韦与非核苷逆转录酶抑制剂利匹韦林。在两项III期非劣效性试验(SWORD-1和SWORD-2)治疗中,将患者的病毒学抑制方案由抗逆转录病毒(ART)方案转变为48周内每日一次的德罗特韦/利匹韦林。观察研究结果表明,转换为德罗特韦/利匹韦林的双药方案后,也表现出了高病毒学抑制。与当前ART方案相比,转换方案后耐受良好,并且表现出更好肾和骨参数。长期结果看来,德罗特韦/利匹韦林表现出持久的病毒学抑制,在长达100周的时间内亦保持良好的耐受性。因此,德罗特韦/利匹韦林为一些感染HIV-1的患者或那些正在采用ART方案或打算更改治疗方案的患者,尽管他们暂时未经历过病毒学抑制失败。
  • 《巴西北部阿马帕州未经抗逆转录病毒治疗的HIV感染者中HIV-1的遗传多态性和传播耐药性研究》

    • 来源专题:艾滋病防治
    • 编译者:门佩璇
    • 发布时间:2015-12-03
    • HIV-1亚型分布模式和传播耐药性(TDRM)在巴西不同区域存在异质性。尤其对于巴西北部地区的分子流行病学数据更是罕见。研究收集了巴西阿马帕州97名未接受抗逆转录病毒治疗(ART)的HIV-1感染者的HIV-1蛋白酶(PR)和逆转录酶(RT)序列,开展了药物耐药突变分析和亚型分析。研究得到,在阿马帕州最流行的HIV-1病毒株为B亚型(74%),其次是F1(14%),BF1重组株(8%),C亚型(1%)CRF31_BC(1%)等。在研究对象中仅有1个TDRM(K103N)被检测出来。该研究结果揭示,相比巴西其他地区,阿马帕州HIV感染者病毒